Brain Tumor Biology

Group leader: Petra Hamerlik

Brain Tumor Biology

Glioblastoma (GBM) is the most prevalent and lethal primary brain tumor. Despite maximal therapeutic intervention, every GBM patient dies of their disease, making therapeutic resistance an urgent area of study.

The main goal of our research is to deepen the understanding of functional interplay between DNA repair mechanisms, cellular hierarchies and therapeutic resistance in GBM. We believe that the identification and successful targeting of mediators of these responses may disrupt resistance to cancer therapies and so fulfil their therapeutic promises.

Petra Hamerlik

Petra Hamerlik

Five selected publications:

Michaelsen, S. R., Staberg, M., Pedersen, H., Jensen, K. E., Majewski, W., Broholm, H., Nedergaard, M. K., Meulengracht, C., Urup, T., Villingshøj, M., Lukacova, S., Skjøth-Rasmussen, J., Brennum, J., Kjær, A., Lassen, U., Stockhausen, M. T., Poulsen, H. S., Hamerlik, P.
VEGF-C sustains VEGFR2 activation under Bevacizumab therapy and promotes glioblastoma maintenance.
Neuro.Oncol. 2018

Staberg, M., Rasmussen, R. D., Michaelsen, S. R., Pedersen, H., Jensen, K. E., Villingshøj, M., Skjøth-Rasmussen, J., Brennum, J., Vitting-Seerup, K., Poulsen, H. S., Hamerlik, P.
Targeting glioma stem-like cell survival and chemoresistance through inhibition of lysine-specific histone demethylase KDM2B.
Mol.Oncol. 2018: 12(3), 406-420

Staberg, M., Michaelsen, S. R., Rasmussen, R. D., Villingshøj, M., Poulsen, H. S., Hamerlik, P.
Inhibition of histone deacetylases sensitizes glioblastoma cells to lomustine.
Cell Oncol.(Dordr.) 2017: 40(1), 21-32

Rasmussen, R. D., Gajjar, M. K., Tuckova, L., Jensen, K. E., Maya-Mendoza, A., Holst, C. B., Møllgaard, K., Rasmussen, J. S., Brennum, J., Bartek Jr., J., Syrucek, M., Sedlakova, E., Andersen, K. K., Frederiksen, M. H., Bartek, J., Hamerlik, P.
BRCA1-regulated RRM2 expression protects glioblastoma cells from endogenous replication stress and promotes tumorigenicity.
Nat.Commun. 2016: 7, 13398

Rasmussen, R. D., Gajjar, M. K., Jensen, K. E., Hamerlik, P.
Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma.
Mol.Oncol. 2016: 10(5), 751-763

ORCID:

Petra Hamerlik

0000-0002-5856-0161